Open Access

Multimodal treatment for resectable epithelial type malignant pleural mesothelioma

  • Ichiro Yoshino1Email author,
  • Masafumi Yamaguchi1,
  • Tatsuro Okamoto2,
  • Chie Ushijima2,
  • Yasuro Fukuyama2,
  • Yukito Ichinose2 and
  • Yoshihiko Maehara1
World Journal of Surgical Oncology20042:11

https://doi.org/10.1186/1477-7819-2-11

Received: 29 September 2003

Accepted: 05 May 2004

Published: 05 May 2004

Abstract

Background

Malignant pleural mesothelioma is a rare malignancy. The outcome remains poor despite complete surgical resection.

Patients and methods

Eleven patients with histologicaly proven epithelial type malignant pleural mesothelioma undergoing extrapleural pneumonectomy with systemic chemotherapy and/or radiotherapy before and after surgical resection were retrospectively reviewed.

Results

Ten out of 11 patients underwent complete surgical resection, of these 7 patients had stage I disease. Of these 7 patients, 5 are alive without any recurrence, a 2-year survival rate of 80% was observed in this group. There was no operative mortality or morbidity.

Conclusion

Extrapleural pneumonectomy with perioperative adjuvant treatment is safe and effective procedure for epithelial type malignant pleural mesothelioma.

Keywords

Extrapleural pneumonectomy hypotonic cisplatin treatment induction chemotherapy gemcitabine vinorelbine cisplatin

Introduction

Malignant pleural mesothelioma (MPM) is a relatively rare entity among intrathoracic malignancies, as compared with lung cancer, although its prevalence has shown an increase in recent years [1]. Extrapleural pneumonectomy (EPP) is the surgical treatment of choice for MPM that do not extend in to the mediastinum or on to the chest wall, although its survival benefit is still not clear [2]. In a retrospective study of 189 Japanese cases [3], there were no significant differences in survival at 2-years between palliative surgery, such as decortication, and EPP (26% and 30%, respectively). EPP with adjuvant chemotherapy and/or radiotherapy has been reported to be effective against the MPM in its early stages [4, 5]. Jaklitsch et al., [6] advocated that EPP plus postoperative chemotherapy using paclitaxel and carboplatin with radiotherapy is effective for MPM if it's of epithelial histology, negative surgical margin, and if extrapleural lymph nodes are negative for metastasis. This study reports on resectable epithelial type MPM with perioperative treatment consisting of radiation and/or chemotherapy.

Patients and methods

Between 1995 and 2002, 10 patients with epithelial type MPM underwent EPP with postoperative or preoperative chemotherapy and/or radiotherapy. The clinical profiles of these patients are detailed in Table 1. The lesions were staged by computed tomographic (CT) scan using International Mesothelioma Interest Group (IMIG) classification. There were 6 stage III, 3 stage II and 1 stage I patient. A bone scan and Magnetic Resonance Imaging (MRI) of the brain were performed if metastasis was suspected. Using the Brigham and Womens Hospital (BWH) staging system of Sugarbaker et al. [4], after the surgical resection 6 patients were stage I, in terms of having completely resected primary tumors including chest wall invasion at the biopsy site.
Table 1

Clinical summary

Case

IMIG stage

BWH stage

Resection

Adjuvant therapy

Recurrence

Survival status/months

1 49 F

III(T3N2M0)

III

Complete

Pre CDDP/Hemithorax RTx

Pericardium

Died 22

2 63 M

III(T3N2M0)

III

Complete

Pre CDDP/Hemithorax RTx

Ipsilateral thorax

Died 30

3 61 M

III(T3N2M0)

III

Incomplete

Pre CDDP/Hemithorax RTx

Ipsilateral thorax

Died 1

4 59 F

III(T1N2M0)

III

Complete

Post CDDP/GEM/UFT

Lung

Dead 28

5 58 M

II(T2N0M0)

I

Complete

Pre CDDP/Hemithorax RTx

None

Alive 28

6 50 M

II(T2N0M0)

I

Complete

Pre CDDP/GEM/VNR

Ipsilateral thorax

Alive 35

7 55 M

II(T2N0M0)

I

Complete

Pre CDDP/GEM/VNR

Pericardium

Died 6

8 66 M

III(T3N0M0)

I

Complete

Pre CDDP/GEM/VNR

None

Alive 15

9 48 M

III(T3N0M0)

I

Complete

Post CDDP/GEM/UFT

None

Alive 32

10 57 M

I(T1N0M0)

I

Complete

Post CDDP/GEM/UFT

None

Alive 39

12 58 M

I(T1N0M0)

I

Complete

Pre CDDP/GEM/VNR

None

Alive 12

IMIG – International mesothelioma Interest group; BWH – Brigham and Women's Hospital; F – Female; M – male; Pre – Pre Operative; Post – Post operativ; CDDP – Cisplatin; RTx – Radiotherapy; GEM – gemcitabine; VNR – Vinorelbine; UFT – Uracil/tegafur

A standard EPP was performed as described earlier [7]. Following a posterolateral incision, extrapleural space was entered from the 5th or 6th rib bed, and dissection was carried superiorly toward the apex, antero- and postero-laterally, and inferiorly toward the diaphragm. During the dissection, port site disease at the chest wall was resected en block. Following an antero-medial pericardiotomy, hilar vessels were resected using a mechanical stapler, followed by resection of the main bronchus. The diaphragm was divided from the peritoneum, and EPP was completed. The defects of pericardium and diaphragm were reconstructed with prosthetic patches. A complete mediastinal lymph node dissection was performed in all cases.

In a preoperative adjuvant setting, one course of concurrent chemoradiotherapy using cisplatin (CDDP) (80 mg/m2, on days 1 and 29) with 40 Gy external beam radiotherapy to the hemithorax [5], was performed in 4 patients (Case 1, 2, 3 and 5) and 2 or 3 courses of chemotherapy using CDDP (40 mg/m2 on days 1 and 8), gemcitabine (GEM) (800 mg/m2, on days 1 and 8), and vinorelbine (VNR) (20 mg/m2, on days 1 and 8) were given at intervals of 3 to 4 weeks in 4 patients (Case 6, 7, 8 and 11) (Table 1). Three patients received 2 courses of postoperative chemotherapy using CDDP (80 mg/m2, on day 1 and 8), GEM (800 mg/m2 on days 8 and 15) and UFT (tegafur/uracil) (400 mg/m2 postoperative on days 1–15) with 3 to 4 weeks interval (Case 4, 9 and 10) (Table 1). One patient received 50 Gy postoperative radiation to the previous thoracic drainage site (Case 10).

Results

Postoperative course of the patients were uneventful, and no morbidity or mortality was experienced. Six patients experienced a relapse in the thorax. One patient underwent resection of the chest wall for recurrence at 12 months after EPP. Other 5 patients (Case 5, 6, 8, 9 and 11) are surviving without any disease. All the survivors had BWH stage I disease, which showed an 80%, 2-year survival. The survival in 4 patients with BWH stage II-III disease was 37% at 2-year. Postoperative chemotherapy was started 2 to 3 months after surgery, and grade 4 neutropenia was observed in all 3 cases, while grade 3 loss of appetite was observed in one. Of the 3 patients who underwent preoperative chemotherapy, a reduction in size of the tumors by 18 to 74% was seen following chemotherapy (Figure 1). Pathological examination of the resected specimens in all 3 cases showed extensive fibrosis with only a small focus of tumor cells (Figure 2). In Case 10, an exploratory thoracotomy was done for suspected recurrence, however, the intrathoracic lesion was found to be a herniated liver from the defect of the reconstructed diaphragm.
Figure 1

The effect of preoperative chemotherapy using CDDP/GEM/VNR in Case 5: Chest CT before (a, b) and after chemotherapy (c, d). The size of the primary tumors, measured two-dimensionally (arrows) decreased by 74% after chemotherapy.

Figure 2

Photomicrograph of case number 5 showing the effect of preoperative chemotherapy. A). Histology of pretreatment biopsy and resected specimen in the above case (× 400, hematoxylin and eosin) B.) Only a small focus of epithelial type mesothelioma cells was found in the resected specimen.

Discussion

Early stage MPM, especially of the epithelial type, is a disease localized to the hemithorax. Therefore, EPP with or without perioperative adjuvant therapy should be effective, as is shown previously. Sugarbaker et al., [4] reported that the treatment with EPP and adjuvant chemotherapy and hemithorax radiotherapy is effective for select patients with MPM. Nearly 50% of the cases who undergo complete resection of epithelial type MPM survive at 5 years. Rusch et al., [5] showed favorable results with EPP followed by radiation. Survival rate at 5-years for patients with stage I/II IMIG classification was 40% [5].

The aim of the perioperative adjuvant therapy is to control tumor cells located at the front line and the lymphatic system and to sterilize the margin of EPP. However, a therapeutically active modality must be considered from the standpoint of patient benefit and safety. The mortality rates for EPP reported in literature are 3.8% by Sugarbaker et al., [4] and 7.9% by Rusch et al., [5]. In our series, all patients returned to active social life following their treatment, indicating that EPP with perioperative adjuvant therapy is well tolerated. Complete resection of capsulated MPM was achieved in 6 cases that had been designated as BWH stage I. Interestingly, as shown in table 1, BWH stage predicted the prognosis well however IMIG stage failed to do so. This indicated that local therapy for epithelial type MPM might be crucial for staging and prognosis as well.

Sugarbaker et al., [4] started chemotherapy using carboplatin and paclitaxel within 4 weeks after EPP. In our series, chemotherapy was started 2 months after EPP in 4 patients who received CDDP/GEM/UFT. Of the 3 patients receiving preoperative chemotherapy using CDDP/GEM/VNR, 2 patients received 2 courses and the other received 3 courses. EPP was performed within 5 weeks after cessation of chemotherapy. The clinical and pathological effects were remarkable. Among chemotherapeutic agents, GEM [8] and VNR [9] are reported to be active and the combination of them with CDDP was used in our study. Neutropenia was the main adverse effect of this regimen observed, which reversed with G-CSF. We therefore suggest that preoperative chemotherapy using such active agents followed by EPP is effective and safe procedure. However, this needs to be tested in a randomized controlled trial.

Declarations

Authors’ Affiliations

(1)
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University
(2)
Department of Thoracic Oncology, National Kyushu Cancer Center

References

  1. Connelly RR, Spirtas R, Myers MH, Percy CL, Frameni JF: Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst. 1987, 78: 1053-1060.PubMedGoogle Scholar
  2. Harvey JC, Fleischman EH, Kagan AR, Streeter OE: Malignant pleural mesothelioma: a survival study. J Surg Oncol. 1990, 45: 40-42.View ArticlePubMedGoogle Scholar
  3. Takagi K, Tsuchiya R, Watanabe Y: Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer. 2001, 31: 57-65. 10.1016/S0169-5002(00)00152-5.View ArticlePubMedGoogle Scholar
  4. Sugarbaker DJ, Flores R, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg. 1999, 117: 54-65.View ArticlePubMedGoogle Scholar
  5. Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996, 111: 815-826.View ArticlePubMedGoogle Scholar
  6. Jaklitsch MT, Grondin SC, Sugarbaker DJ: Treatment of malignant mesothelioma. World J Surg. 2001, 25: 210-217. 10.1007/s002680020021.View ArticlePubMedGoogle Scholar
  7. Garcia JP, Richards WG, Sugarbaker DJ: Surgical treatment of malignant mesothelioma. In Mastery of cardiothoracic surgery. Edited by: Kaiser LR, Kron IL, Spray TL. 1998, Lippincott-Raven, Philadelphia, New York, 230-236.Google Scholar
  8. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson WS: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999, 17: 25-30.PubMedGoogle Scholar
  9. Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000, 18: 3912-3917.PubMedGoogle Scholar

Copyright

© Yoshino et al; licensee BioMed Central Ltd. 2004

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Advertisement